Methods of development and utilization or randomized evidence in guidelines for advanced gynecological malignancies.

<p>*the reference sources for the assignment of levels of evidence are as follows:</p>(1)<p><a href="http://www.cancer.gov/cancertopics/pdq/levels-evidence-adult-treatment/HealthProfessional/page2" target="_blank">http://www.cancer.gov/cancertopics/pdq/levels-evidence-adult-treatment/HealthProfessional/page2</a>;</p>(2)<p>Scottish Intercollegiate Guidelines Network. Methodology Review Group. Report on the review of the method of grading guideline recommendations. Edinburgh: SIGN; 1999.;</p>(3)<p>Cook DL, Guyatt GH, Laupacis A, et al: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 102:305S–311S, 1992 (suppl 4);</p>(4)<p>National Health and Medical Research Council (NHMRC). How to Use the Evidence: Assessment and Application of Scientific Evidence. Canberra, Australia: NHMRC; 2000;</p>(5)<p><a href="http://www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual4.htm" target="_blank">http://www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual4.htm</a>;</p>(6)<p>FIGO guidelines present a grading system for level of evidence (A–D) without specifying which system used.</p

Distribution of organizations by location, society and organization type.

(a)<p>Continental American organizations include all USA national organizations along with 2 other South American organizations.</p>(b)<p>“Other” refers to any society setting that does not belong to any of the above specialty settings. This may include other specialty societies or other societies such as guideline developers.</p

Entities with guidelines for advanced stage gynecologic malignancies.

<p>Entities with guidelines for advanced stage gynecologic malignancies.</p